Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Londo who wrote (5830)	3/8/2002 9:02:37 PM
From: John Metcalf	Respond to of 52153

"And in a way, it's also to the benefit of the consumer. Imagine what crap there would be out there if there was no such thing as a double-blinded clinical trial? Would you be willing to bet your life on IMC-C225's Phase II data? Didn't think so." Londo, I agree with the point you are making, but I want to suggest a couple other points of view: 1) The Ph II IMC-225 trial participants _did_ bet their lives on an unapproved drug, with only _Ph I_ data available. The Ph III participants will have the Ph II data available to them. They are still betting their lives on an unapproved treatment. 2) If a physician tells me "hopeless" at some point in the future, I will likely make the same decision that trial participants have made.